Livalo Related Published Studies
Well-designed clinical trials related to Livalo (Pitavastatin)
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. [2011.09]
The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia. [2011.07]
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. [2011.07]
Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. [2011.07]
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. [2011.05.25]
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. [2011.02]
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a
randomized controlled trial. [2011]
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). [2010.06]
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). [2010.05.25]
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. [2010.03]
Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. [2010.01]
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. [2010.01]
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. [2009.11]
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. [2009.10]
Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. [2009.08]
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). [2009.07.21]
The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. [2009.02]
Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. [2009.02]
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). [2008.12]
Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies. [2008.06.01]
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. [2008.06]
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. [2008.05]
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. [2008.05]
Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. [2008.04]
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. [2007.11]
Well-designed clinical trials possibly related to Livalo (Pitavastatin)
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study. [2010.10.27]
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. [2010.09]
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. [2009.05]
Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): rationale and design. [2009.02]
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. [2009.02]
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. [2008.06]
Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. [2008.04]
Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. [2007.09]
Other research related to Livalo (Pitavastatin)
Pitavastatin: a review of its use in the management of hypercholesterolaemia or
mixed dyslipidaemia. [2012]
The clinical impact of pitavastatin: comparative studies with other statins on
LDL-C and HDL-C. [2012]
Randomized comparison of pitavastatin and pravastatin treatment on the reduction
of urinary albumin in patients with type 2 diabetic nephropathy. [2012]
Meta-analysis of the comparative efficacy and safety of pitavastatin and
atorvastatin in patients with dyslipidaemia. [2012]
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. [2011.11]
Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. [2011.10.01]
Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. [2011.10]
[Prediction of the pharmacokinetic drug-drug interaction of pravastatin and pitavastatin with cyclosporine by a digital liver model based on metabolism and transporter]. [2011.09]
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. [2011.08]
Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? [2011.08]
Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. [2011.06.28]
Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia. [2011.06.01]
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. [2011.05.18]
Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. [2011.05]
Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. [2011.02]
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. [2011.01.31]
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. [2011.01]
Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. [2011.01]
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. [2011]
Clinically evident polyvascular disease and regression of coronary
atherosclerosis after intensive statin therapy in patients with acute coronary
syndrome: serial intravascular ultrasound from the Japanese assessment of
pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. [2011]
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and
atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined
(mixed) dyslipidaemia. [2011]
Randomized head-to-head comparison of pitavastatin, atorvastatin, and
rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL
trial. [2011]
Comparison of efficacy of pitavastatin and colestimide in Japanese patients with
diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. [2011]
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in
patients with Type 2 diabetes mellitus. [2011]
Pitavastatin prevents postprandial endothelial dysfunction via reduction of the
serum triglyceride level in obese male subjects. [2011]
Pitavastatin - from clinical trials to clinical practice. [2010.12]
Pitavastatin - results from phase III & IV. [2010.12]
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia. [2010.11.02]
Pitavastatin - a novel therapeutic milestone. [2010.10]
Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. [2010.08]
Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. [2010.07]
Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. [2010.06.30]
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. [2010.06]
Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice. [2010.06]
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. [2010.05]
Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. [2010.04]
New evidence on pitavastatin: efficacy and safety in clinical studies. [2010.04]
Pitavastatin: a new HMG-CoA reductase inhibitor. [2010.03]
Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. [2010.03]
Pitavastatin: the newest HMG-CoA reductase inhibitor. [2010.01]
Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound--the TOGETHAR trial. [2010]
Pitavastatin approved for treatment of primary hypercholesterolemia and combined
dyslipidemia. [2010]
Diabetes mellitus is a major negative determinant of coronary plaque regression
during statin therapy in patients with acute coronary syndrome--serial
intravascular ultrasound observations from the Japan Assessment of Pitavastatin
and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). [2010]
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in
patients with hypercholesterolemia. [2010]
Pitavastatin: a new HMG-CoA reductase inhibitor. [2010]
Co-administration of ezetimibe enhances proteinuria-lowering effects of
pitavastatin in chronic kidney disease patients partly via a
cholesterol-independent manner. [2010]
Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. [2009.10]
Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. [2009.10]
Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. [2009.09]
Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. [2009.08]
Pitavastatin fails to lower serum lipid levels or inhibit gastric carcinogenesis in helicobacter pylori-infected rodent models. [2009.08]
Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. [2009.08]
Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. [2009.06]
Pitavastatin prevents intestinal ischemia/reperfusion-induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia. [2009.05]
Effects of pitavastatin on cerebral blood flow. [2009.03]
Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor kappaB pathway. [2009.02]
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. [2009]
Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. [2008.12]
Other possibly related research studies
More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome. [2010.07.28]
Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? [2010.06.01]
Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. [2010.03]
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. [2010.01]
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. [2011.09.14]
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. [2011.09]
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. [2011]
Gateways to clinical trials. [2010.11]
Cardiovascular diseases. Introduction. [2010.12]
Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions. [2010.09]
|
